The changes of serum acidic markers in human subjects receiving pharmacological dosage of antispasmodics.
BACKGROUND
Anticholinergic and glucagon result in the diminished gastric acid secretion, it is unknown whether these agents may again influence serum acidic markers.


METHODS
The changes of serum levels of acidic markers represented with gastrin and pepsinogen I at 10 min after the injection of either hyoscine-N-butyl-bromide (HNBB) 20 mg (n = 31) or glucagon 1 mg (n = 32) were investigated when these subjects were receiving endoscopic retrograde cholangiopancreatography for various reasons.


RESULTS
At this period, both medications exerted an antispasmodic action on the duodenum. An anticholinergic effect was seen only among the HNBB group, whereas hyperglycemia appeared among the glucagon group. HNBB did significantly inhibit serum pepsinogen I levels when compared with their basal levels (mean +/- SD: 92.1 +/- 33.2 ng/ml vs. 83.2 +/- 27.4 ng/ml, P < 0.01). However, HNBB did not influence serum gastrin levels. Glucagon inhibited both serum pepsinogen I (89.1 +/- 39.7 ng/ml vs. 80.5 +/- 37.4 ng/ml, P < 0.005) and gastrin (79.3 +/- 31.3 pg/ml vs. 71.3 +/- 23.8 pg/ml, P < 0.01) levels compared with their basal levels.


CONCLUSIONS
Present observations indicate that glucagon and HNBB may inhibit serum PGI level, whereas the former has the additional effect of inhibiting serum gastrin level.
Guo
W S
WS
Department of Medicine, 803 Army General Hospital, Taichung, Taiwan, R.O.C.
Chang
F Y
FY
Liao
T M
TM
Lee
S D
SD
D002086:Butylscopolammonium Bromide / Q000008:administration & dosage / Q000494:pharmacology*; D002760:Cholangiopancreatography, Endoscopic Retrograde; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000097:blood*; D005934:Glucagon / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010435:Pepsinogens / Q000097:blood*
D005755:Gastrins; D010435:Pepsinogens; D002086:Butylscopolammonium Bromide; D005934:Glucagon